Compare H2O America (HTO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Recursion Pharmaceuticals Inc — how do they compare? H2O America trades at $62.3 (market cap $2.61B), while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.81B). The key difference: H2O America is the larger of the two by market cap, and H2O America pays a 2.83% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| HTO | RXRX | |
|---|---|---|
Market Cap | $2.61B | $1.81B |
Sector | Technology | Health |
52-Week High | $65.43 | $6.79 |
52-Week Low | $44.44 | $2.84 |
Enterprise Value | $4.40B | $1.33B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $62.42, up 1.92% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a 12.91% net income margin and consistent earnings beats in recent quarters. Recent news highlights transformative acquisitions in Texas, though dilution risks exist. Institutional interest is strong, with Fifth Third Bancorp increasing its stake by 3,753.2% in Q1 2026 (SEC filing, 2026-07-30).
Outlook is positive with an 83.33% analyst buy rating and a consensus price target of $69.50, implying ~11% upside. Risks include execution challenges from acquisitions and potential EPS pressure from equity issuance. The dividend yield remains supported, but growth sustainability depends on operational efficiency amid expansion.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
